A Phase 1/2 interventional study of Entrectinib in Solid Tumors and CNS Tumors, sponsored by Hoffmann-La Roche. Active, not recruiting at 26 sites in 9 countries. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
How we know · 16 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Central Nervous System Neoplasms with a site in United States — 45 open to participants now, 74 under way, 3 of them phase 3. Central Nervous System Neoplasms · United States.
Among the 547 studies in Central Nervous System Neoplasms with a site in United States, this one is the 95th largest by enrollment of the 399 interventional ones that give a count, is one of 8 that started in 2016, is one of 70 in phase 1/2, reaches primary completion later than 34 of the 73 other live ones, and was the 418th registered.
699 studies on the registry are indexed under Central Nervous System Neoplasms; 65 are open to participants now.
Browse Central Nervous System Neoplasms studies →45 of the 547 studies in Central Nervous System Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Neonc Technologies, Inc. · Sites in United States
Ages 5–18
BrainChild Bio, Inc · Sites in United States
Ages 1–26
Robbie Majzner · Sites in United States
Ages 2–21
University of California, Irvine · Sites in United States
Ages 18+
National Institute of Neurological Disorders and Stroke (NINDS) · Sites in United States
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 56 Central Nervous System Neoplasms studies recruiting now, 34 (61%) set no upper age limit and 19 (34%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 0 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 256 · Phase 2 241 · Phase 3 22 · Phase 4 1
First in 1989; this study’s year is marked. 8 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is above the median of 35 across 487 interventional studies indexed under Central Nervous System Neoplasms.
Median enrollment 31 across the 399 interventional studies, 109 across the 68 observational. Of the 436 that completed or were terminated, 109 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 547 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 2 studies filed under Central Nervous System Neoplasms — fewer than ten, so there is no comparison to draw.
23 of the studies in Central Nervous System Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT05664243In8bio Inc.A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | 2026-12 |
| NCT05425004Baptist Health South FloridaCabozantinib for Patients With Recurrent or Progressive Meningioma | 2026-12 |
| NCT05762419Columbia UniversityFUS Etoposide for DMG | 2026-12 |
| NCT04992013Massachusetts General HospitalNiraparib in Tumors Metastatic to the CNS | 2026-12-01 |
Add all 23 to your calendar (.ics) → With an account.
Among the 547 studies in Central Nervous System Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Disease status:
Phase 2 portion:
Tumor type:
Phase 1 portion:
* Part A: extracranial solid tumors
Phase 2 portion
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm closed for further enrollment ROS1, ALK non-gene fusion molecular alterations Oral entrectinib (RXDX-101)
Drug: Entrectinib
Arm closed for further enrollment molecular alterations, including gene fusions Oral entrectinib (RXDX-101)
Drug: Entrectinib
Arm closed for further enrollment Oral entrectinib (RXDX-101)
Drug: Entrectinib
Arm closed for further enrollment harboring - NTRK1/2/3, ROS1, ALK gene fusions Oral entrectinib (RXDX-101)
Drug: Entrectinib
Arm closed for further enrollment Any participant who otherwise meet all other eligibility criteria Oral entrectinib (RXDX-101)
Drug: Entrectinib
gene fusions Oral entrectinib (RXDX-101)
Drug: Entrectinib
NTRK 1,2,3 and ROS1 fusions Oral entrectinib (RXDX-101)
Drug: Entrectinib
TRKA/B/C, ROS1, and ALK inhibitor
Also known as: RXDX-101
Maximum Tolerated Dose (MTD)
Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03)
Time frame: Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Assessed by NCI CTCAE v4.03
Time frame: Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Assessed by NCI CTCAE v4.03
Time frame: Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube)
Assessed by NCI CTCAE v4.03
Time frame: Approximately 6 months
Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules
Assessed by NCI CTCAE v4.03
Time frame: Approximately 6 months
Cohort B: Objective Response Rate (ORR)
Assessed by RANO per the BICR
Time frame: Approximately 6 months
Cohort D: ORR
Assessed by RECIST v1.1 per the BICR
Time frame: Approximately 6 months
Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03
AE, ECG and Labs assessed by NCI CTCAE v4.03
Time frame: Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F1 Formulation
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F06 Formulation given intact
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F06 Formulation administered via feeding tube
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using minitablets/F15
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Time to Cmax, by inspection (Tmax) using F1 Formulation
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Time to Cmax, by inspection (Tmax) using F06 Formulation given intact
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Time to Cmax, by inspection (Tmax) using F06 Formulation administered via feeding tube
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Time to Cmax, by inspection (Tmax) using minitablets/F15
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
AUC at steady state (AUCss) using F1 Formulation
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
AUC at steady state (AUCss) using F06 Formulation given intact
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
AUC at steady state (AUCss) using F06 Formulation administered via feeding tube
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
AUC at steady state (AUCss) using minitablets/F15
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Terminal half life (t½) using F1 Formulation
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Terminal half life (t½) using F06 Formulation given intact
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Terminal half life (t½) using F06 Formulation administered via feeding tube
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Terminal half life (t½) using minitablets/F15
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Area under the drug concentration by time curve (AUC) using F1 Formulation
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Area under the drug concentration by time curve (AUC) using F06 Formulation given intact
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Area under the drug concentration by time curve (AUC) using F06 Formulation administered via feeding tube
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Area under the drug concentration by time curve (AUC) using minitablets/F15
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter
Time frame: Approximately 24 months
Cohort A, D, or E: Clinical Benefit Rate (CBR)
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Cohort B or E: CBR
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Cohort C: CBR
Assessed by the Curie scale per the BICR and investigator
Time frame: Approximately 6 months
Cohort A, D, or E: Progression-free Survival (PFS)
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Cohort B or E: PFS
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Cohort C: PFS
Assessed by the Curie scale per the BICR and investigator
Time frame: Approximately 6 months
Cohort A, D, or E: Overall Survival (OS)
Assessed by RECIST v1.1
Time frame: Approximately 6 months
Cohort B or E: OS
Assessed by RANO
Time frame: Approximately 6 months
Cohort A, D, or E: ORR
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Cohort B or E: ORR
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Cohort C: ORR
Assessed by the Curie scale per the BICR and investigator
Time frame: Approximately 6 months
Cohort A, D, or E: Time to response (TTR)
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Cohort B or E: TTR
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Cohort C: TTR
Assessed by the Curie scale per the BICR and investigator
Time frame: Approximately 6 months
Cohort A, D, or E: Duration of Response (DOR)
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Cohort B or E: DOR
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Cohort C: DOR
Assessed by the Curie scale per the BICR and investigator
Time frame: Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Assessed by RANO per the investigator
Time frame: Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): ORR
Assessed by RECIST v1.1 per the investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): ORR
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): ORR
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): ORR
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): ORR
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): ORR
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): DOR
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): DOR
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): DOR
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): DOR
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): DOR
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): DOR
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): TTR
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): TTR
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): TTR
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): TTR
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): TTR
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): TTR
Assessed by RECIST v1.1 per the BICR and investigator
Time frame: Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Assessed by RANO per the BICR and investigator
Time frame: Approximately 6 months
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.
Started May 2016 (actual). Primary completion is estimated for Jun 2027, 133 months after the start.
Of 35 phase 1/2 interventional studies under Central Nervous System Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 85. This study's planned 133 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Entrectinib
Central Nervous System Neoplasms →